Peptide research glossary: analytical and pharmacological terms

Analytical terms

Chromatographic purity. The area of the target peak as a percentage of total integrated peak area in an HPLC run at a stated wavelength. It measures composition among UV-absorbing species, not mass fraction of the vial.

Net peptide content. The proportion of the vial's contents that is peptide by mass, after accounting for residual water and counter-ions such as trifluoroacetate. Typically 75–90 percent for lyophilized material. This, not the label strength, is the figure used for accurate molar calculations.

Identity. Confirmation that the compound present is the compound named, established by mass spectrometry matching the observed mass to the theoretical mass of the stated sequence and its terminal modifications.

Deletion sequence. A chain missing one or more residues because a coupling step failed during synthesis. Chemically similar to the target and closely co-eluting, which is why purification rather than synthesis sets the achievable purity.

Lot. A discrete manufactured batch. Analytical data is only meaningful when tied to a specific lot number that matches the vial in hand.

Chemistry and formulation terms

Lyophilization. Freeze-drying: water is frozen and then removed by sublimation under vacuum, leaving an amorphous solid cake that is far more chemically stable than the same peptide in solution.

Reconstitution. Returning lyophilized material to solution by adding a diluent, normally bacteriostatic or sterile water, directed down the vial wall rather than onto the cake.

Counter-ion. The charged species paired with the peptide after purification, most often trifluoroacetate. It contributes mass without contributing peptide.

Amidation and acetylation. Terminal modifications that cap the C-terminus and N-terminus respectively, altering charge, mass and protease susceptibility. Both must be reflected in the theoretical mass on the certificate.

Excipient. Any non-peptide component added to a formulation, such as mannitol as a bulking agent. Research-grade peptides are frequently supplied without excipients, which is one reason cake appearance varies.

Pharmacological terms

Agonist. A ligand that binds a receptor and produces a response. A full agonist elicits the maximal response the system supports; a partial agonist plateaus below it and can behave as a functional antagonist when a full agonist is present.

EC50 and IC50. The concentration producing half the maximal effect, and the concentration producing half-maximal inhibition, respectively. Both are potency measures and neither describes the size of the maximal effect.

Efficacy. The magnitude of the maximal response a ligand can produce. Independent of potency: a more potent compound can be less efficacious.

Biased agonism. Preferential activation of one downstream pathway over another at the same receptor, classically G-protein signalling versus beta-arrestin recruitment. Two ligands with matched cAMP potency can differ substantially in receptor internalisation.

Half-life. The time for concentration to fall by half in a given system. Frequently engineered independently of receptor affinity through lipidation, albumin binding or protease-resistant substitutions.

Supply and compliance terms

Research use only (RUO). A designation indicating material is manufactured and released against research specifications and supplied for in vitro and appropriately approved preclinical work. It carries no sterility, endotoxin, GMP or regulatory safety evaluation.

Certificate of analysis (COA). A lot-specific analytical report. A complete one names the issuing laboratory, states the lot, the report date, the method conditions, the HPLC purity result and the mass-spectrometry identity result.

Third-party testing. Analysis performed by a laboratory independent of the manufacturer and the seller. Vendor-generated summaries without an independent issuer are not third-party data.

Retest or expiry date. The end of the period over which the material is expected to remain within its stated specification when stored as directed. It is a specification statement, not a safety claim.

Analytical terms that appear on every certificate

Assay, in a peptide certificate, means measured content — how much target peptide the vial actually contains, usually as a percentage of nominal fill or in milligrams. It is distinct from purity, which is the proportion of detected peptide-related material that is the target. Net peptide content is the same idea expressed after subtracting counter-ion and moisture, and is the figure quantitative work should use.

Related substances are impurities structurally close to the target — deletion sequences missing a residue, truncated chains, oxidised or deamidated forms. They are the impurities that matter analytically because they are the hardest to resolve and the most likely to co-elute. Residual solvent and residual TFA describe process leftovers rather than sequence-related species.

Endotoxin units per milligram quantifies bacterial lipopolysaccharide by the limulus amebocyte lysate assay. It is unrelated to chromatographic purity and is the decisive specification for cell-culture work, because endotoxin activates innate immune signalling at picogram concentrations.

Pharmacology vocabulary used across compound pages

Affinity describes how tightly a ligand binds its receptor and is reported as Kd or Ki. Potency describes the concentration producing half the maximal functional effect and is reported as EC50 or IC50. Efficacy describes the size of that maximal effect. A compound can bind tightly and produce a small response, or bind weakly and produce a large one; the three terms are independent and are routinely conflated in secondary sources.

Agonist, partial agonist, antagonist and inverse agonist describe direction and ceiling of effect. An allosteric modulator acts at a site away from the natural ligand's and changes the response to it rather than producing one directly. Biased agonism describes preferential activation of one downstream pathway over another at the same receptor.

Half-life, clearance and exposure describe what happens to a molecule rather than what it does at the receptor. Modifications such as acylation, pegylation and albumin-binding linkers act on these properties, which is why they can transform an in vivo result while barely registering in a receptor assay.